Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1992 1
1994 2
1995 1
1996 1
2001 1
2006 2
2007 2
2010 1
2011 3
2012 1
2013 5
2014 7
2015 5
2016 3
2017 2
2018 6
2019 4
2020 7
2021 4
2022 5
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Results by year

Filters applied: . Clear all
Page 1
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study.
Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, Iravani A, Kong G, Ravi Kumar A, Murphy DG, Eu P, Jackson P, Scalzo M, Williams SG, Sandhu S. Hofman MS, et al. Among authors: eu p. Lancet Oncol. 2018 Jun;19(6):825-833. doi: 10.1016/S1470-2045(18)30198-0. Epub 2018 May 8. Lancet Oncol. 2018. PMID: 29752180 Clinical Trial.
Dosimetry of 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer: Correlations Between Pretherapeutic Imaging and Whole-Body Tumor Dosimetry with Treatment Outcomes.
Violet J, Jackson P, Ferdinandus J, Sandhu S, Akhurst T, Iravani A, Kong G, Kumar AR, Thang SP, Eu P, Scalzo M, Murphy D, Williams S, Hicks RJ, Hofman MS. Violet J, et al. Among authors: eu p. J Nucl Med. 2019 Apr;60(4):517-523. doi: 10.2967/jnumed.118.219352. Epub 2018 Oct 5. J Nucl Med. 2019. PMID: 30291192 Free article. Clinical Trial.
Radiolabelled Aptamers for Theranostic Treatment of Cancer.
Khalid U, Vi C, Henri J, Macdonald J, Eu P, Mandarano G, Shigdar S. Khalid U, et al. Among authors: eu p. Pharmaceuticals (Basel). 2018 Dec 24;12(1):2. doi: 10.3390/ph12010002. Pharmaceuticals (Basel). 2018. PMID: 30586898 Free PMC article. Review.
Pulmonary Deposition of Radionucleotide-Labeled Palivizumab: Proof-of-Concept Study.
Rajapaksa AE, Do LAH, Suryawijaya Ong D, Sourial M, Veysey D, Beare R, Hughes W, Yang W, Bischof RJ, McDonnell A, Eu P, Yeo LY, Licciardi PV, Mulholland EK. Rajapaksa AE, et al. Among authors: eu p. Front Pharmacol. 2020 Aug 19;11:1291. doi: 10.3389/fphar.2020.01291. eCollection 2020. Front Pharmacol. 2020. PMID: 32973520 Free PMC article.
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT).
Emmett L, John N, Pathmanandavel S, Counter W, Ayers M, Sharma S, Agrawal S, Poole A, Hovey E, Pranavan G, Gedye C, Mallesara G, Guminski A, Lee A, Stockler MR, Hickey A, Eu P, Joshua AM, Crumbaker M, Nguyen A. Emmett L, et al. Among authors: eu p. Ther Adv Med Oncol. 2023 Mar 1;15:17588359231156392. doi: 10.1177/17588359231156392. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 36872949 Free PMC article.
The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET/CT and 18F-FDG PET/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I/II Trial (LuPIN).
Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, Ayers M, Sharma S, Eu P, Martin AJ, Stockler MR, Joshua AM, Emmett L. Pathmanandavel S, et al. Among authors: eu p. J Nucl Med. 2023 Jan;64(1):69-74. doi: 10.2967/jnumed.122.264104. Epub 2022 Jun 23. J Nucl Med. 2023. PMID: 35738906 Free PMC article. Clinical Trial.
53 results